Although BsAbs targeting CTLA-4 have been a significant breakthrough in the field of cancer immunotherapy, there are still numerous aspects that require clarification and challenges that need to be addressed related to the safety, effectiveness, and range of tumors that could be treated. Here, CTLA4 is linked to cancer.